Structural gray matter alterations in glioblastoma and high-grade glioma-A potential biomarker of survival
- PMID: 37152811
- PMCID: PMC10162111
- DOI: 10.1093/noajnl/vdad034
Structural gray matter alterations in glioblastoma and high-grade glioma-A potential biomarker of survival
Abstract
Background: Patients with glioblastoma (GBM) and high-grade glioma (HGG, World Health Organization [WHO] grade IV glioma) have a poor prognosis. Consequently, there is an unmet clinical need for accessible and noninvasively acquired predictive biomarkers of overall survival in patients. This study evaluated morphological changes in the brain separated from the tumor invasion site (ie, contralateral hemisphere). Specifically, we examined the prognostic value of widespread alterations of cortical thickness (CT) in GBM/HGG patients.
Methods: We used FreeSurfer, applied with high-resolution T1-weighted MRI, to examine CT, evaluated prior to standard treatment with surgery and chemoradiation in patients (GBM/HGG, N = 162, mean age 61.3 years) and 127 healthy controls (HC; 61.9 years mean age). We then compared CT in patients to HC and studied patients' associated changes in CT as a potential biomarker of overall survival.
Results: Compared to HC cases, patients had thinner gray matter in the contralesional hemisphere at the time of tumor diagnosis. patients had significant cortical thinning in parietal, temporal, and occipital lobes. Fourteen cortical parcels showed reduced CT, whereas in 5, it was thicker in patients' cases. Notably, CT in the contralesional hemisphere, various lobes, and parcels was predictive of overall survival. A machine learning classification algorithm showed that CT could differentiate short- and long-term survival patients with an accuracy of 83.3%.
Conclusions: These findings identify previously unnoticed structural changes in the cortex located in the hemisphere contralateral to the primary tumor mass. Observed changes in CT may have prognostic value, which could influence care and treatment planning for individual patients.
Keywords: biomarker of GBM and HGG; brain tumor; cortical thickness; glioblastoma and high-grade glioma; overall survival.
© The Author(s) 2023. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
Conflict of interest statement
E.C.L. has equity in Neurolutions, Inner Cosmos. E.C.L., D.S.M., and C.D.H. have equity in Sora Neuroscience. E.C.L, J.J.L., and J.S.S. have patent interests licensed to Sora Neuroscience. D.S.M. has equity in Radiologics, Inc. Washington University has equity in Neurolutions. B.L and E.C.L. have filed a provisional patent on the techniques described in this manuscript. All other authors declared that they had no conflicts of interest to their authorship or the publication of this article.
Figures
References
-
- Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–466. - PubMed
-
- Julkunen V, Niskanen E, Koikkalainen J, et al. Differences in cortical thickness in healthy controls, subjects with mild cognitive impairment, and Alzheimer’s disease patients: a longitudinal study. J Alzheimers Dis. 2010;21(4):1141–1151. - PubMed